Patents by Inventor Alan Crossman

Alan Crossman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7935718
    Abstract: The present invention relates to the use of compounds that enhance H3-histamine receptor activity, or activation (e.g. H3-histamine receptor agonists) for the treatment of dyskinesia. The compounds are particularly useful for treating dyskinesia associated with parkinsonian therapy.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: May 3, 2011
    Assignee: Motac Neuroscience Limited
    Inventors: Jonathan Brotchie, Michael Hill, Alan Crossman
  • Publication number: 20060069039
    Abstract: The present invention relates to the treatment of dyskinesia with compounds of General Formula (I) such as topiramate. The compound may be topiramate or a derivative thereof. The dyskinesia may be associated with a basil ganglia-related movement disorder such as parkinsonism and may also arise as a side-effect of other therapeutic agents (e.g. L-DOPA).
    Type: Application
    Filed: September 1, 2003
    Publication date: March 30, 2006
    Inventors: Alan Crossman, Michael Hill, Jonathan Brotchie, Montague Silverdale
  • Publication number: 20050261282
    Abstract: The present invention relates to compounds, related to 2,3 benzodiazepines, of general formula (I), such as Tofisopam, Girisopam or Nerisopam, for use in the treatment of dyskinesia. The dyskinesia may arise as a side-effect of a therapy for pakinsonism.
    Type: Application
    Filed: September 11, 2003
    Publication date: November 24, 2005
    Applicant: Motac Neuroscience Limited Williams House
    Inventors: Alan Crossman, Michael Hill, Jonathan Brotchie
  • Publication number: 20050245587
    Abstract: The present invention relates to the use of compounds that enhance H3-histamine receptor activity, or activation (e.g. H3-histamine receptor agonists) for the treatment of dyskinesia. The compounds are particularly useful for treating dyskinesia associated with parkinsonian therapy.
    Type: Application
    Filed: October 28, 2004
    Publication date: November 3, 2005
    Applicant: MOTAC NEUROSCIENCE LIMITED
    Inventors: Jonathan Brotchie, Michael Hill, Alan Crossman
  • Publication number: 20030139438
    Abstract: The present invention relates to a method of diagnosis of the parkinsonian condition in presymptomatic subjects. Additionally, the invention relates to a method for the differential diagnosis of early Parkinson's disease and differentiating Parkinson's disease patients from patients with other movement disorders.
    Type: Application
    Filed: November 21, 2002
    Publication date: July 24, 2003
    Inventors: Jonathan Brotchie, Michael Hill, Alan Crossman, Erwan Bezard
  • Publication number: 20030109504
    Abstract: The present invention relates to the use of compounds, which inhibit metabotropic glutamate receptor activity, or activation, for use in the treatment of movement disorders associated with a poverty of movement (e.g. Parkinson's disease). The compounds are particularly useful when used in combination with another therapeutic agent and surprisingly reduce the extent and incidence of side effects (e.g. dyskinesia) associated with such therapeutic agents.
    Type: Application
    Filed: November 14, 2002
    Publication date: June 12, 2003
    Inventors: Jonathan Brotchie, Michael Hill, Alan Crossman